Back to All Collaborations

AMR Industry Alliance

Active Since: 2017

Multi-Company Partnership

Contributing to SDGs…

The AMR Industry Alliance is one of the largest private sector coalitions set up to provide sustainable solutions to curb antimicrobial resistance, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces.

MEMBER COMPANIES

PARTNER ORGANISATIONS

  • Academia or research institute

    IMMT

  • Hospitals/Health Facilities

    Oragenics

  • Pharma (Non-IFPMA Member)

    Athalone Laboratories

    Viatris

    LOCUS Biosciences

    Clarametyx Biosciences

    vitas Pharma

    Xellia Pharmaceuticals

    Taxis Pharmaceuticals

    TetraPhase Pharmaceuticals

    Pheerecydes Pharma

    Paratek

    MicuRx

    FEDORA Pharmaceuticals

    Destiny Pharma

    Blueberry Therapeutics

  • Professional and trade associations

    Medicines for Europe

    UK BioIndustry Association

    European Federation of Pharmaceutical Industries and Associations (EFPIA)

    British In Vitro Diagnostic Association (BIVDA)

    British Generic Manufacturers Association

    Biotechnology Industry Organization (BIO)

    BEAM Alliance

    Antimicrobial Innovation Alliance

    Association for Accessible Medicines (AAM)

    Vereniging Innovatieve Geneesmiddelen

    Advanced medical Technology Association (AdvaMed)

  • Generic manufacturers

    Aurobindo Pharma Ltd

    Centrient Pharmaceuticals

    Frasenius Kabi

    Recipharm

    Venus

  • Life sciences

    Biomerieux

    Cepheid

    Curetis

    HemoCue

    MeMed

    MOBIDING

    NEMIS Technologies

    Quantum MD

    Spectromics

    Northern Antibiotics

    Agile Sciences

    AiCuris

  • Technology

    Aequor

    BD (Becton Dickinson)

    Venatorx

    VibioSphen

    Synthetic Genomics

    UNION Therapeutics

    SOLIGENIX

    SPERO Therapeutics

    SPEXIS

    Summit Therapeutics

    Rebiotix

    SCYNEXIS

    SetLance

    SinSa Labs

    Phare Bio

    PHICO Therapeutics

    POLYPHOR

    NovaDigm Therapeutics

    OJBIO

    Peptilogics

    Nosopharm

    NovaBiotics

    Mutabilis

    Nabriva Therapeutics

    iNtRON Biotechnology

    meiji

    Melinta Therapeutics

    Microbion Corporation

    FORGE Therapeutics

    HELPERBY

    CURZA

    ELIGO BIoscience

    FASTinov

    Bugworks

    Combioxin

    ContraFect

    AntibioTx

    AUROBAC Therapeutics

    BIOVERSYS

    Allecra Therapeutics

    Alphanosos

    Amplyx

    ANTABIO

    ABAC Therapeutics

Objectives

The AMR Industry Alliance aims to contribute sustainable solutions to curb antimicrobial resistance by creating a broad industry momentum and facilitating collaboration between the public and private sectors.

The life sciences industries are a crucial partner in efforts to curb AMR. Within this context, the AMR Industry Alliance (AMRIA) was established in 2017 and brings together leading biopharmaceutical, biotechnology, diagnostic, generics companies and industry associations to address AMR-related issues.

The principles of the AMR Industry Alliance are based on its two founding documents: the Davos Declaration and the Industry Roadmap. Since then, Alliance commitments have evolved in line with industry progress and global priorities.

The Alliance measures and drives the life-sciences industry progress to curb antimicrobial resistance in four different areas: research and science, appropriate use, access, manufacturing.

RESEARCH & SCIENCE 

  • Invest in research and development for innovative antibiotics and antibiotic dosage forms, vaccines, new technologies, and diagnostics.
  • Continue to advocate for policies that support sustainable investment in AMR-relevant innovation.
  • Partner with policymakers, payers, and other relevant stakeholders on new reimbursement, valuation, and commercial models that support appropriate patient access and a sustainable supply of antibiotics and AMR-relevant vaccines and new technologies and diagnostics.
  • Support collaboration and sharing of relevant non-proprietary data with different stakeholders (e.g., academia, consortia, small or medium-sized enterprise (SMEs), public researchers and industry) to help address key scientific and public health challenges.

ACCESS 

  • Address barriers to patient access to the most appropriate treatment, vaccine, or diagnostic.
  • Work in collaboration with policymakers to create an economic and regulatory environment that enables the sustainable supply of quality-assured antibiotics.
  • Work to reduce the prevalence of substandard and falsified AMR-relevant products.

APPROPRIATE USE 

  • Contribute to slowing the emergence of resistance by preventing infections by promoting vaccination and reduction of inappropriate use of antibiotics through expanded use of diagnostics.
  • Support appropriate use of antibiotics by working closely with other partners on awareness campaigns, continued education for healthcare professionals, and generation of evidence to support appropriate use and stewardships.
  • Collect and share surveillance data with public health bodies and healthcare professionals to improve understanding of resistance trends, monitor the effectiveness of antibiotics, inform appropriate antibiotic and vaccine use, and develop adapted infection control strategies.
  • Ensure that any promotional activities for antibiotics are aligned with the goal of advancing stewardship.

MANUFACTURING AND ENVIRONMENT 

  • Review Alliance member’s own manufacturing and supply chains to assess good practice in controlling release of antibiotics into the environment.
  • Establish a common framework for managing antibiotic discharge, and start to apply it across their own manufacturing and supply chains by 2018.
  • Work with stakeholders to develop a practical mechanism transparently show that Alliance member supply chains meet the frameworks standards.
  • Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations of antibiotics and develop good practice methods to reduce environmental impacts of manufacturing discharges by 2020.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs
  2. 3.8: Achieve universal health coverage

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

  • The AMR Industry Alliance’s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). The progress reports can be accessed here.
  • The AMR Industry Alliance has been driving responsible manufacturing of antibiotics. This has been a step-wise approach, first with the establishment of science-based predicted no-effect concentration (PNECs) targets, helping minimize antibiotic resistance and environmental toxicity. Another major milestone was achieved in 2018, with Alliance members agreeing on a framework that promotes responsible antibiotic manufacturing. In June 2022, the Alliance took this work one step further and published its Antibiotic Manufacturing Standard: “Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics”. The Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly. More details can be found here.
  • The AMR Industry Alliance has established an annual Stewardship Prize, to acknowledge organizations in low- and middle-income countries who use innovative approaches to AMR stewardship in their communities, with the goal of helping these organizations further scale their promising practices. More information about the Prize can be found here.

ADDITIONAL INFORMATION

Geographic Reach

Global Commitment

Disease Area

Infectious and Parasitic Disease

  • Drug-Resistant Infections (AMR)